Sector News

Amgen to Cut About 300 Jobs as it Combines Cancer Work With Onyx

March 11, 2015
Life sciences
Amgen plans to cut about 300 jobs and close one of its South San Francisco buildings as part of a reorganization that will combine cancer organization with Onyx Pharmaceuticals, which the biotech bought for $10.4 billion.
 
The shine on the Onyx acquisition – and the Kyprolis cancer drug that was the Onyx crown jewel – brightened recently after a company-sponsored study found that Kyprolis patients lived twice as long as patients taking the rival treatment Velcade before their multiple myeloma worsened.
 
Yet Amgen, which is bsaed in Thousand Oaks, Ca., has been laying off employees and closing buildings as it launches new drugs and prepares for more. The biotech is also facing competition for some of its medications and pressure from an activist investor, Daniel Loeb, whose Third Point fund took a stake in Amgen last year and recommended reducing what it termed the company’s “bloated cost structure.”
 
Onyx brought 750 jobs to Amgen, as well as a building in South San Francisco, not far from an Amgen research site, an Amgen spokeswoman says.
 
In a memo to staff on Tuesday, Amgen ceo Robert Bradway wrote that 300 Onyx jobs would be cut and Onyx headquarters in South San Francisco would be shuttered. “These combined oncology capabilities will create the focus and efficiency Amgen requires to progress our vision in oncology, and to remain a world leader for the long term,” he wrote.
 
The cuts, first reported by Xconomy, are part of a larger reorganization that will merge the cancer teams into a single organization, Bradway noted, adding that he expects Amgen to retain all of the Onyx sales and medical staffs, while shifting some Onyx researchers to Amgen laboratories in South San Francisco. However, Xconomy noted that the fate of another 200 Onyx employees is uncertain.
 
By Jonathan Rockoff
 
comments closed

Related News

June 14, 2025

UCB touts plan for major US investment to boost biologics capacity

Life sciences

In a press release Thursday, UCB revealed a plan to establish a “new, state-of-the-art biologics manufacturing facility in the United States.” The company hasn’t settled on the exact location, but it says the site will create 300 high-skilled jobs once complete.

June 14, 2025

Schott Pharma invests in sterile cartridge production

Life sciences

Schott Pharma has expanded its Lukácsháza site with a new facility for prefillable glass syringes, which are used for GLP-1 therapies, vaccines, and biologics. Since opening in June 2024, the site has added 120 employees, begun production, and increased capacity.

June 14, 2025

Vitafoods Europe 2025: Barcelona debut delivers scale, energy and innovation

Life sciences

LinkedIn Twitter Xing EmailThis year marked a significant milestone for the nutraceutical industry as Vitafoods Europe made its highly anticipated move from Geneva to Barcelona, drawing a record-breaking 25,500+ attendees […]

How can we help you?

We're easy to reach